Trial Profile
Consecutive blood letting and peginterferon alfa-2a/ribavirin standard treatment compared to peginterferon alfa-2a/ribavirin standard treatment alone for treatment-naive patients with hepatitis C virus genotype one and elevated ferritin levels.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jan 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms KAPRI
- 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 30 Jun 2009 Primary endpoint 'Viral-kinetic-parameters' has not been met.
- 30 Jun 2009 Status changed from not stated to completed as reported by ISRCTN: Current Controlled Trials.